Aurora BioPharma CEO Joins Dignitaries During AANS Annual Scientific Meeting in Chicago
CAMBRIDGE, MA - April 30, 2016 - Aurora BioPharma CEO, Robert Brooks, joins dignitaries and leaders from the American Association of Neurological Surgeons (AANS) and other neurosurgical organizations during the 2016 AANS Annual Scientific Meeting to be held April 30 - May 4th in Chicago, IL. The American Association of Neurological Surgeons (AANS) is dedicated to advancing the specialty of neurological surgery around the world. The meeting features a collaboration with the Federacion Latinoamericana de Sociedades de Neurocirugia (FLANC) and the Pan Arab Neurosurgical Society (PANS).
About Aurora BioPharma
Aurora is leading in the development of Chimeric Antigen Receptor (CAR) T therapy, Cancer Vaccines, and combinations with Checkpoint Inhibitors. AU105 is a "living-drug" CAR T agent that has shown safety and efficacy in pre-clinical and human clinical trials. A Phase 1 was completed in 16 Glioblastoma patients, AU105 met its endpoints of safety, tumor killing efficacy, and showed promising signals of double the median historic overall survival. Aurora is planning a randomized multi site Phase II trial of AU105 in Early Diagnosed Glioblastoma, and a Phase I/II trial in Recurrent Glioblastoma with intracranial injection. Osteosarcoma is the most common type of bone cancer in Children and Adolescents, even after a radical amputation of a limb and chemotherapy, survival is poor. A Phase 1 trial in 19 Sarcoma patients was completed, AU-105 met its endpoints of safety, with strong signs of tumor killing efficacy. Aurora is planning a Phase II trial of its CAR T Cell therapy AU105 in Osteosarcoma. The Company also has an equity interest in MedVax Technologies, Inc., its p53 DC cancer vaccine MX-225 has completed a Phase II clinical trial in Small Cell Lung Cancer; and soon to complete a phase II trial in Breast Cancer with Indoximod, an IDO inhibitor from NewLink Genetics. The Company is planning a combination trial with MX-225 and a PD-1 antibody in lung cancer with a major pharmaceutical company.
The American Association of Neurological Surgeons (AANS) is the organizations that speaks for all of neurosurgery. Founded in 1931 as the Harvey Cushing Society, the American Association of Neurological Surgeons (AANS) is a scientific and educational association with more than 9,000 members worldwide. Fellows of the AANS are board-certified by the American Board of Neurological Surgery, the Royal College of Physicians and Surgeons of Canada, or the Mexican Council of Neurological Surgery. A.C. Neurosurgery is the medical specialty concerned with the prevention, diagnosis, treatment and rehabilitation of disorders that affect the spinal column, spinal cord, brain, nervous system and peripheral nerves.
For media inquiries, please contact:
Tel: (617) 674-7718 - Fax (617) 674-7701
Source: Aurora BioPharma, Inc.